Label counts behind armodafinil side effects

The label counts armodafinil side effects that led people to stop.

In placebo-controlled clinical trials, 44 of the 645 patients (7%) who received NUVIGIL discontinued due to an adverse reaction compared to 16 of the 445 (4%) of patients that received placebo.

In the trials, 44 of the 645 patients (7%) who received NUVIGIL stopped.

On placebo, 16 of the 445 patients (4%) stopped.

The label says the most frequent reason for stopping was headache (1%).

The label says serious rash has been reported with NUVIGIL (armodafinil) or modafinil.

The highlights say to stop NUVIGIL at the first sign of rash.

They add one exception: a rash that is clearly not drug-related.

Follow your doctor for any decision about this drug.

DailyMed label

Sources